[HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018].
PMID: 34814456
2021
Zhonghua liu xing bing xue za zhi
Abstract: The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%).
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Abstract: The performance of the PANDAA assay in screening K65R, K103NS, M184VI, Y181C, and G190A mutations compared to the reference assay, Sanger sequencing was evaluated by Cohen s kappa coefficient on Stata version 14 (StataCorp LP, College Station, TX, USA).
Abstract: We assessed the performance of a rapid HIV-1 drug resistance assay, the Pan Degenerate Amplification and Adaptation (PANDAA) assay when screening for significant HIV-1 drug resistance mutations (DRMs) such as K65R, K103NS, M184VI, Y181C and G190A.
Introduction: Briefly, the PANDAA assay is an allelic discrimination test designed with different
Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
Result: In addition, the OLA did not detect resistance to NNRTI in one participant with V106M and Y188C, or resistance to 3TC in four participants with M184I, as these mutations were not interrogated by the OLA.
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Conclusion: Our structures also explain a common mechanism for 3TC/ETV resistance by severe steric clash between the M184V/I (M204V/I in HBV) side-chain and the oxathiolane/methylene of boun
Result: M184V/I in HIV-1 RT has long been known as a critical 3TC-resistant-associated mutation in HIV-1.
Result: One possible solution to overcome M184V/I (M204V/I in HBV) resistance is to decrease composition for NRTIs that do not rely on the interactions with Met184.
Result: Thus, a M184V/I steric clash would likely occur when 3TC-TP tightly binds to the N-site, as observed in this study.
Result: Thus, a nearly identical ETV/3TC resistance mechanism appears to work for resistance to ETV and 3TC with M184I.
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
PMID: 31965175
2020
The Journal of infectious diseases
Abstract: In RT, 9 nonpolymorphic TSMs occurred in >=10 persons: K40R, A62V, K70R, Y115F, Q151M, M184VI, S215Y.
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%).
Result: However, when we compared individual mutations we found that M184V/I (p = 0.015), Y188L (p = 0.008) and TAMs (p = 0.011) were significantly more common in Subtype A as compared to Subtype D and others.
Result: When we compared individual mutations within the NRTI class, M184V/I mutation had the highest prevalence of 120 (65.9%) among patients.
Discussion: However, M184V/I (67 (55.8%), p = 0.015), Y188L (9 (100%), p = 0.008) and TAMs (44 (51.8%),
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 32065630
2020
The Journal of antimicrobial chemotherapy
Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.
Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Abstract: In addition, this case highlights the need for viral load monitoring in patients on dolutegravir-containing regimens in settings with a high prevalence of the M184V/I mutation such as in low-income countries.
Abstract: This case illustrates that dolutegravir-containing triple-therapy should be prescribed with caution to patients with pre-existing M184V/I mutation and poor efficacy of the reverse transcriptase inhibitor backbone.
Abstract: We describe a rare case of a patient with pre-existing M184V/I mutation and virological failure on a dolutegravir/lamivudine/abacavir regimen with the emergence of integrase strand transfer inhibitor resistance mutations.
Result: The genotypic resistance test using Sanger technology revealed the M184I mu
HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.
Abstract: Antiretroviral resistance was detected in 21.5% of 93 pol sequences analyzed, with the M184I/V and K103N mutations that confer high-level resistance to NRTI and NNRTI, respectively, being the most frequent mutations.
Result: Among the 7 cases with NRTI mutations, the most common was M184I/V, which is known to confer high-level resistance to both emtricitabine (FTC) and 3TC.
HIV mutation literature information.
PMID: 
2021
Zhonghua liu xing bing xue za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT